Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Conclusion: Trastuzumab does not decrease the detection rate of CTCs in HER2 non-amplified, non-metastatic breast cancer.
PMID: 29893791 [PubMed - as supplied by publisher]

Source: Ann Oncol - June 11, 2018 Category: Cancer & Oncology Authors: Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY Tags: Ann Oncol Source Type: research